Medtronic has received the CE mark for its CoreValve system, used for direct aortic and subclavian transcatheter aortic valve implantation in patients with severe aortic stenosis.

This direct treatment option is designed to provide aortic stenosis patients with an alternative therapy to the transfemoral, transapical and subclavian artery approaches.

Earlier studies showed that the direct aortic approach demonstrates high procedural success rates and overall survival rates.

The new treatment will allow for easier manipulation and placing of the valve because of the short distance from access site to implantation site.

Currently, the Medtronic CoreValve system is limited to investigational use in the US.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.